
As of 30-JUN-2026, promoters held 57.49% of Cohance Lifesciences (0.00 pp from 31-MAR-2026), foreign institutional investors 6.50%, domestic institutions 20.09%, the government 0.01% and the public 15.92%.
Source: Shareholding patterns filed with the stock exchanges (company filings). Data as of 7 October 2026. How this data is compiled.
Promoters held 57.49% of Cohance Lifesciences as of 30-JUN-2026, unchanged from 57.49% in 31-MAR-2026.
Foreign institutional investors held 6.50% of Cohance Lifesciences as of 30-JUN-2026, a change of +0.91 pp from the previous quarter.
Domestic institutional investors, including mutual funds and insurers, held 20.09% of Cohance Lifesciences as of 30-JUN-2026 (-1.70 pp from the previous quarter).
As of 30-JUN-2026, Cohance Lifesciences' shareholders were promoters (57.49%), foreign institutional investors 6.50%, domestic institutions 20.09%, the government 0.01% and the public 15.92%, as filed with the stock exchanges.
Track COHANCE live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.